Group items tagged

PRODUCT DESCRIPTION DERMA ROLLER SYSTEM IN PAKISTAN Derma Roller Price In Pakistan Anti Wrinkle / Anti Aging Treatment in Openteleshop.com.The Derma Roller System Can Be Used To Treat Creases In The Skin Of The Forehead (Scowl Lines), Deep Wrinkles, Fine Wrinkles, Skin Creases And Lines, Wrinkles Around The Mouth, On The Neck And Jaw Line, The Decolletes (Chest), On The Backs Of The Hands And More. CELLULITE TREATMENT / CELLULITE REDUCTION OR REMOVAL|OPENTELESHOP Cellulite Removal/reduction Can Be Accomplished With Regular Treatment Using The Derma Roller System in Openteleshop. The Derma Roller System Can Be Used To Remove/reduce Cellulite Commonly Found On Arms, Buttocks, Hips, Legs, Thighs And Stomach.. HAIR LOSS TREATMENT / HAIR RESTORATION (USED WITH MINOXIDIL 5%) The Derma Roller System Can Be Used To Effectively Prevent And Stop Hair Loss From Occuring. The Derma Roller System in Openteleshop. Can Help With Hair Restoration And Regrowth By Both Men And Women Who Are Experiencing Alociepia, Balding, Bald Spots, Receding Hairlines And Thinning Hair. A Recent Trial Conducted Over A 3 Month Period Showed That Men With Thinning Hair Who Used The Derma Roller System Experienced Both An Increase In Hair Growth And An Average Of 80% Reduction In Hair Loss. Note: For Hair Regrowth And Hair Loss Prevention, The Derma Roller Must Be Used With Minoxidil 5% (Available At Your Local Pharmacy). Scar Removal - Including Acne Scar Removal The Derma Roller System Is Effective In Acne Scar Removal And Acne Scar Treatment, As Well As Treating Appdectomy Scars, Breast Augmentation Scars, Burn Scars, C-Section Scarring, Chicken Pox Scars, Ice Pick Scars, Large Pores, Pitting Of The Skin, Surgical Scars, Tummy Tuck Scars And More. SKIN SMOOTHING:OPENTELESHOP The Derma Roller System Is An Effective Way To Smoothen Your Skin. By Stimulating Collagen And Elastin And Repairing Your Skin From The Inside, Your Skin Will Stay Beautiful Even As You Get Older. The Derma Roller Sys

New data on weight loss drugs that could compete with Novo Nordisk's Wegovy are raising expectations there will soon be more options, and possibly lower prices, in an estimated $100 billion marketplace, doctors and pharmaceutical executives say. Drugmakers are ratcheting up their research and aiming for new formulations that can be taken as pills, options to deliver higher weight loss or drugs that reduce fat while maintaining muscle. "It has really been an explosion of innovation," said Dr. Robert Gabbay, chief science officer at the American Diabetes Association (ADA), which receives funding from both Novo and Eli Lilly and Co and just concluded its annual meeting in San Diego, California. "If there are multiple (treatments) in the market, that will lead to some level of competition and greater access."

The Medicines and Healthcare products Regulatory Agency (MHRA) has cautioned against buying weight-loss medicines without a prescription from beauty salons, unregistered pharmacy websites or social media platforms as such products could pose "serious health risks." Consumers are reminded that the only safe way to obtain genuine weight-loss medication is through a legitimate pharmacy, including licensed online pharmacies, with a prescription from a qualified healthcare professional. To combat the illegal sale of these medicines, the MHRA's Criminal Enforcement Unit is working closely with social media platforms, technology companies, the police and Border Force. Andy Morling, MHRA deputy director of Criminal Enforcement, highlighted the dangers of purchasing these medications from unverified sources: "At this time of year, with many of us thinking about shedding a little excess weight, we see people offering weight loss medicines for sale as a quick fix, without a healthcare professional's prescription, from beauty salons, websites and on social media. "These are not cosmetic treatments; they are powerful medicines that can only be legally and safely dispensed against a prescription issued by a healthcare professional."

Kent and Medway prescribe the highest number of semaglutide, liraglutide and tirzepeptide - drugs that are commonly used for treating type 2 diabetes, weight loss, or both - in the UK, according to recent research by Click Pharmacy. Called GLP-1 agonists, these drugs mimic the effects of the GLP-1 hormone, which is released by the body after eating. This hormone slows digestion, stimulates insulin release, and inhibits glucagon, a hormone that raises blood sugar, making GLP-1 agonists effective treatments for diabetes and weight management. The online pharmacy's research reveals that Kent and Medway prescribed the most of these drugs in the month of June 2024, with 6,326 prescriptions. Other NHS Integrated Care Boards (ICBs) with high prescription rates included: Black Country and West Birmingham (5,019) Hampshire, Southampton, and Isle of Wight (4,960) Birmingham and Solihull (4,775) North Central London (4,528) North East London (3,557) North West London (3,498) Cambridgeshire and Peterborough (2,973) Coventry and Warwickshire (2,912) Norfolk and Waveny (2,575) Brighton and Hove topped the list for prescribing Wegovy, a weight-loss drug containing semaglutide, with 35 prescriptions made out in June alone.

With Novo Nordisk's patent protection for liraglutide now expired, the UK is set to welcome the first wave of generic weight loss medicines. The British Generic Manufacturers Association (BGMA), the trade body for off-patent medicines, believes these generic versions could "provide could provide much-needed capacity to meet growing demand and alleviate shortages." Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is primarily used to treat type 2 diabetes and obesity. Novo Nordisk markets liraglutide under the brand names Victoza (for type 2 diabetes and Saxenda (for weight loss). In a statement released on 20 November 2024, the BGMA confirmed that "liraglutide's patent protection was no longer in force, marking the first time generic versions of diabetes and weight loss treatments can be available in the UK." The BGMA anticipates that at least four companies will obtain UK marketing authorisations for generics targeting type 2 diabetes and obesity. However, it remains uncertain how many will launch immediately.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes. Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION). To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly "opens the possibility of an end to the obesity pandemic" alongside other interventions, the World Health Organisation (WHO) said this week. But the global health agency said it has concerns that unless health systems prepare properly, the drugs could distort the response to the global obesity crisis, risking leaving people behind and overshadowing other steps to improve health. The new drugs "have the potential to be transformative", according to the WHO's chief scientist, Jeremy Farrar, its director of nutrition, Francesco Branca, and his senior adviser, Francesca Celleti, in an opinion piece in the Journal of the American Medical Association (JAMA). The article is the agency's clearest comment yet on the potential of the new drugs, known as GLP-1 receptor agonists. But "medication in isolation will not be enough to address the obesity crisis," they added, calling instead for the innovation to push clinicians, governments, the pharmaceutical industry and the public towards considering the condition a chronic disease that needs further study into how best to prevent and treat it.

A diabetes medicine, Mounjaro, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat overweight patients. The weight loss medication originally developed for Type 2 diabetes is now accessible to individuals aged 18 and over who are dealing with obesity and weight-related health issues. The active ingredient, tirzepatide, works by making the patient feel fuller and reducing food cravings. The injection helps individuals lose 20 per cent of their body weight, and are advised to follow a reduced-calorie diet and increase physical activity simultaneously. Although it is not authorised to use on the NHS as yet but future approvals can be predicted.

People are advised to be mindful of medications that may cause sun reactions, and to watch out for dodgy hay fever treatments and fake weight loss pens. For those traveling abroad, the MHRA advises considering the suitability of medicines available to reduce the risk of contracting tropical diseases. Dr Alison Cave, Chief Safety Officer at the MHRA, said: "The summer is an exciting time for many of us, as we take time off to travel and enjoy the warmer weather. "But it is important to understand what this time of year means for our medicines and medical devices, and take the precautions necessary to use products safely and protect ourselves." Watch out for dodgy hay fever treatments Millions of Britons suffer from hay fever symptoms in the summer. The MHRA advises consulting a healthcare professional to find the best treatment for your symptoms. People are also warned to be cautious of medicines advertised as hay fever treatments but not approved for use in the UK, such as Kenalog. This is a prescription-only steroid injection licensed as a medicine for other conditions, but not for the treatment of hay fever.

Eli Lilly's weight-loss medicine Mounjaro, also known as tirzepatide, will be available in the UK within weeks as a four-dose pre-filled injection pen. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the drug to treat adults with type 2 diabetes and for weight management in obese patients. Branded as Mounjaro KwikPen, the injection is to be used together with a reduced-calorie diet and increased physical activity, the regulator said. "The public health importance of safe and effective treatments to help manage diabetes and obesity, which can have a significant impact on people's health, is clear. "This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month's treatment, of one dose per week," said Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access.

Pediatric Wheelchair is designed especially for children and offers the maximum in safety and comfort that is sure to put smiles on the faces of parents and children alike.The precision crafted reclining mechanism provides ultra smooth reclining performance and comes standard with swing away detachable elevating legrests. Pediatric wheelchairs are provided unsurpassed quality and style, specializing in compact-folding, lightweight wheelchairs for children of all ages - from toddlers to teens! Custom built to your child's specific needs, our mobility aids offer rehabilitative benefits for physical disabilities from Cerebral Palsy to Autism.

Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or delayed development in the brain. The disorder is permanent and, though it does not worsen with age, the level of functionality of a person with cerebral palsy varies widely: in some cases, effects may be very minor, while in others, movement is impaired to the extent that a wheelchair is required. Common complications associated with CP vary by the type of CP disorder but can include vision problems, seizures, learning disabilities, and issues speaking, writing, and performing other tasks. Cerebral palsy causes problems with muscle tone, movement, balance and/or coordination. Symptoms and effects range from mild to severe. In some infants, problems are evident soon after birth. In others, diagnosis comes in later infancy or toddlerhood. Cerebral Palsy Wheelchair Description: The model designed for cerebral palsy child only. Ultra light weight aluminium alloy frame. Seat Width 38 cms (15"). Net Weight: 18.5 kgs. Epoxy powder coated frame. Detachable arm rest & foot rest provided. Elevated and swinging foot rest. Elevated foot rest provided to elevate leg angle. Height adjustable and detachable head rest. Hydraulic reclining high back for a comfortable posture. Hydraulic adjustable seat angle. Detachable back and seat pad. Extra cushion upholstery provided to under arm, head & calg Foldable. Lever and paddle brakes provided. Safety belt provided. Maintenance free rear solid wheels. Cloth look like water proof upholstery. Anti wheels for better safety and stability. Extra cushion upholstery provided to under arm, head & leg Folding action. Lever and paddle brakes provided. Safety belt provided. Maintenance free rear solid wheels. Cerebral Palsy Wheelchair Recline system: Recline system provides kids with the most comfortable resting environment. It also allows stretching abdomin

Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through registered healthcare professionals. Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK. The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage. "We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access to and continuity of treatment for people living with obesity."

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication of semaglutide (Wegovy), authorising its use to reduce the risk of serious heart problems and strokes in adults who are obese or overweight. Semaglutide, a GLP-1 receptor agonist, was previously approved for use in the treatment of obesity and weight management, to be used alongside diet, physical activity and behavioural support. The latest approval establishes it as the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal stroke, in people with established cardiovascular disease and a Body Mass Index (BMI) higher or equal to 27 kg/m2. Novo Nordisk, the manufacturer of Wegovy, received this authorisation on 23 July following compelling evidence from a recent post-approval clinical study involving over 17,600 participants. The study demonstrated that Wegovy, administered at a dose of 2.4 mg once weekly via subcutaneous injection for up to five years, significantly lowers the incidence of major adverse cardiovascular events (MACE) by 20 per cent compared to a placebo.

Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to 19 per cent weight loss after 46 weeks in a mid-stage trial. The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation. Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called glucagon that helps break down fat.

The General Pharmaceutical Council (GPhC) is inviting feedback on proposed changes to its guidance for online pharmacies, aimed at enhancing patient safety. These changes are designed to tackle concerns associated with receiving medicines from online pharmacies, particularly those that may not be clinically appropriate and could potentially harm patients. GPhC has identified concerns relating to inappropriate supplies of weight loss medications that could pose risk to patients' health. Duncan Rudkin, Chief Executive of the GPhC, underscored the importance of addressing risks in online pharmacy services. "We know that there can be significant benefits for people using online pharmacy services to get medicines and treatment, but there are also additional risks that need to be managed, to make sure medicines and other pharmacy services are provided safely to patients and the public.